![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 06, 2020 1:01:43 PM
Yes, Mike Scott in center of table.
https://twitter.com/UCLTRO/status/1238161125948166145/photo/1
I expect Sawston licensing in the second half of June.
Join us on 11 March 2020 for an exclusive London Advanced Therapies ATN, powered by MedCity event on ATMP manufacturing in the UK, with leading academic and industry expert panellists.
Why ATMP Manufacturing?
The UK is one of the leading sources of research and development in advanced therapies, with over 900 therapeutic developers, 1,060 clinical trials and 14 approved ATMPs (ARM and BIA 2019). With 25 manufacturing facilities across the UK, we are competitively positioned as a leading global hub in the field, but key challenges remain to be addressed, particularly when it comes to manufacturing at scale.
Investment, funding opportunities, viral vector manufacturing capacity and the right skills and talent are all challenges facing both academia and industry, whose capacity to translate research into clinical products is at critical levels.
This event will bring together leading academic and industry experts to discuss the current state of play in this landscape, along with the challenges and the way forward. We will also look at how to translate current ATMP manufacturing capabilities into clinical excellence, and the important role investment is playing in the race for global leader status.
Agenda
• 16:30 Registration, tea and coffee
• 17:00 Opening Remarks – Dr Francesca Gliubich, Director of London Advanced Therapies
• 17:10 Session 1: The ATMP manufacturing landscape in the UK and the current challenges
•
o 17:10 – Keynote – Ian McCubbin, OBE, Chair RoslinCT and Manufacturing advisory group Innovate
o 17:25 – Panel Discussion
•
o
?
? Prof Uta Griesenbach, Imperial College London
? Matthew Durdy, CBO, Cell and Gene Therapy Catapult
? Dr James Miskin, CTO, Oxford Biomedica
? Prof Farzin Farzaneh, King’s College London
? Peter Coleman, CEO, Cobra Biologics
? Dr Mike Scott, COO, Advent Bioservices
• 18:10 Session 2: Translating the UK ATMP manufacturing capabilities to clinical excellence and the role of investment
•
o 18:10 – Keynote – Dr Eliot Forster, CEO, F- Star and Chairman, MedCity
o 18:25 – Panel Discussion
? Prof Emma Morris, UCL and UCLH
? Dr Jacqueline Barry, CCO, Cell and Gene Therapy Catapult
? Prof Andrew Baker, University of Edinburgh
? Prof Adrian Thrasher, UCL
? Dr Catriona Crombie, LifeArc
•
o 19:10 Closing Remarks – Dr Pamela Tranter, Head, Translational Research, UCL
o 19:20 – 20:30 Networking reception
https://www.medcityhq.com/news-and-events/
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM